A Stromal CTHRC1 Biomarker Framework May Identify Colorectal Cancers With Poor Prognosis and Limited Immunotherapy Benefit

Highlights

In a retrospective multiomic analysis of more than 3000 colorectal cancer samples, a distinct fibroblast population marked by collagen triple helix repeat containing 1 (CTHRC1) emerged as a clinically relevant stromal biomarker.

CTHRC1-positive cancer-associated fibroblasts (CAFs) were consistently associated with enhanced transforming growth factor-beta (TGF-beta) signaling, worse outcomes in early and advanced colorectal cancer, and a stromal program linked to treatment resistance.

Comments

No comments yet. Why don’t you start the discussion?

Leave a Reply